MaxCyte Inc. (NASDAQ:MXCT) is one of the best penny stocks under $1 to buy right now. On February 24, MaxCyte launched the ExPERT DTx, which is a high-throughput 96-well electroporation platform ...
ExPERT DTx streamlines workflows by processing up to 96 samples in a single, three-minute run. The platform’s R-50x96™ well processing assembly provides one of the most cost-effective solutions for 96 ...
Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Cell Transfection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's offering ...
VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable ...
Modifying gene-delivery approaches for lymphocytes is critical for both fundamental research and clinical immunotherapy. T cells, B cells, and natural killer (NK) cells are difficult to transfect, and ...
Tumoroids, also known as cancer organoids, are three-dimensional (3D) in vitro cell cultures established from primary tissue samples. These next-generation cancer cell models largely recapitulate the ...
Are low gene editing efficiency or gene expression levels preventing your research from advancing? Is your transfection method killing your cells? Are you struggling to reproduce your initial results ...
From its earliest days, MaxCyte had a vision: Helping clients turn cells into cell therapies. And now this vision is becoming reality. A few isolated, laboratory-scale exercises will soon become a ...
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma. In part 1 of our interview with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results